Prime Medicine, Inc. Common Stock (PRME)
Prime Medicine, Inc. (PRME) is a biotechnology company focused on developing gene editing therapies for genetic diseases. Leveraging its Prime Editing technology, the company aims to create precise, efficient, and versatile treatments to address a range of genetic conditions, with an emphasis on improving patient outcomes through innovative genomic editing solutions.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| September 12, 2019 | $0.80 | 2019-09-10 | 2019-09-11 |
| June 28, 2019 | $0.20 | 2019-06-14 | 2019-06-17 |
| December 31, 2018 | $0.21 | 2018-12-18 | 2018-12-19 |
| September 28, 2018 | $0.23 | 2018-09-14 | 2018-09-17 |
| June 29, 2018 | $0.15 | 2018-06-21 | 2018-06-22 |
Dividends Summary
- Prime Medicine, Inc. Common Stock has issued 15 dividend payments over the past 4 years
- The most recent dividend was paid 2233 days ago, on September 12, 2019
- The highest dividend payed out to investors during this period was $0.86 per share
- The average dividend paid during this period was $0.26 per share.
Company News
Prime Medicine reported Q2 2025 earnings with a net loss of $52.6 million, below analyst estimates. The company demonstrated clinical proof-of-concept for Prime Editing in chronic granulomatous disease and extended its cash runway into 2027 through strategic restructuring and funding.
Prime Medicine is conducting a public offering of 38 million shares at $3.30 per share, expecting to raise approximately $125.4 million. The Cystic Fibrosis Foundation will purchase 1,818,181 shares, and the offering is expected to close on August 1, 2025.
Prime Medicine and Bristol Myers Squibb have entered a strategic research collaboration and license agreement worth over $3.5 billion. Prime Medicine will design optimized Prime Editor reagents for Bristol Myers Squibb's next-generation cell therapies, with Prime Medicine eligible for upfront and milestone payments.
We have narrowed our search to five small-cap biotech stocks with strong potential for the rest of 2024. These are: ARQT, BCYC, CSTL, PRME, LXRX.